Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Total Liabilities: 2017-2025

Historic Total Liabilities for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $87.6 million.

  • Puma Biotechnology's Total Liabilities fell 41.46% to $87.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.6 million, marking a year-over-year decrease of 41.46%. This contributed to the annual value of $121.2 million for FY2024, which is 31.55% down from last year.
  • As of Q3 2025, Puma Biotechnology's Total Liabilities stood at $87.6 million, which was down 2.89% from $90.2 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Total Liabilities registered a high of $242.2 million during Q1 2021, and its lowest value of $87.6 million during Q3 2025.
  • Over the past 3 years, Puma Biotechnology's median Total Liabilities value was $156.5 million (recorded in 2024), while the average stood at $140.9 million.
  • Per our database at Business Quant, Puma Biotechnology's Total Liabilities increased by 12.06% in 2021 and then crashed by 42.36% in 2025.
  • Puma Biotechnology's Total Liabilities (Quarterly) stood at $229.0 million in 2021, then declined by 12.48% to $200.5 million in 2022, then dropped by 11.66% to $177.1 million in 2023, then tumbled by 31.55% to $121.2 million in 2024, then crashed by 41.46% to $87.6 million in 2025.
  • Its last three reported values are $87.6 million in Q3 2025, $90.2 million for Q2 2025, and $99.1 million during Q1 2025.